USO 26064

Isang Pandaigdigan, Interbensyonal, at Bukas-label na Pagsubok ng T-DXd-based Therapy na Sinundan ng Palbociclib, Endocrine Therapy at Dual HER2 Blockade sa First-line HER2+/HR+ Advanced o Metastatic Breast Cancer at Retreatment gamit ang T-DXd (DESTINY-Breast Guide) Protocol: DS8201-0004-CIS-MA

Mga Uri ng Sakit: Pananaliksik sa Kanser sa Suso

Mga Kinakailangan sa Kwalipikasyon:

• Histologically confirmed HR+ and HER2+ la/MBC (local testing)
• No prior chemotherapy or HER2-targeted tx for MBC
• If treated in (neo)adjuvant setting, pt are eligible if DFI >6 months from
completion of systemic tx to PD
• Previous T-DXd tx for eBC with an EFS or DFI of <12 months from
completion of T-DXd tx in the neoadjuvant or post-neoadjuvant setting
are excluded
• 1 prior line of ET tx for MBC is allowed
• Prior tx with any CDK inhibitor are excluded
• > 1 measurable lesion or non-measurable bone-only disease or lytic/mixed
lytic bone lesions assessable by CT, MRI, or X-ray
• Asymptomatic brain metastases (<2 cm) or treated metastases that are no
long symptomatic and requires no treatment are eligible
• Adequate treatment washout period before enrollment (check full protocol
for details.

Para sa karagdagang impormasyon sa pagsubok na ito CLICK HERE .

Available sa:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach ( Princess Anne )
• Williamsburg